ORO Labs Named Top Procurement Technology Provider at 2025 World Procurement Awards
Hosted annually by Procurement Leaders, the awards celebrate the individuals, teams, and companies setting new benchmarks for innovation, performance, and impact across the global procurement function. ORO was selected for its AI-powered orchestration platform, which delivers intuitive user experiences and enables businesses to shorten cycle times, reduce risk through end-to-end process visibility, and stay agile with a platform specifically designed for procurement teams.
'Procurement touches every corner of business operations, yet it's often slowed down by manual, fragmented systems that make it hard to move at the speed organizations actually need,' said Sudhir Bhojwani, Co-Founder and CEO of ORO. 'We built ORO to cut through that friction — to give teams what they need, without frustration. This award is a meaningful validation that when procurement is connected, agile, and user-first, it becomes one of the most powerful drivers of business impact.'
ORO's platform simplifies the source-to-pay process by connecting systems, people, and policies across the enterprise. Designed for scale, it helps teams automate compliance, streamline workflows, and adapt in real time to changing business needs, without losing control or visibility. In a year defined by rapid market and regulatory change, AI acceleration, and global supply chain disruption, ORO is helping leading enterprises move faster, stay compliant, and navigate change with confidence – a challenge Bayer, a global life sciences leader, is tackling head-on with ORO.
'ORO is a true AI innovation partner helping us work toward our vision of a zero-bureaucracy experience,' said Thomas Udesen, CPO at Bayer.
The award follows a year of strong growth and recognition for ORO, including the acquisition of ProcureTech, leadership in Spend Matters' 2025 SolutionMap for Intake and Orchestration and in IDC's inaugural MarketScape, and several award wins from Supply & Demand Chain Executive. To learn more, visit orolabs.ai.
About ORO Labs
ORO Labs is a procurement orchestration company on a mission to humanize the procurement experience by coordinating teams, systems, and processes so employees get what they need without frustration. ORO's AI-powered no-code platform is purpose-built to deliver effortless user experiences that enable businesses to reduce cycle times, decrease risk through end-to-end process visibility, and increase agility in response to change. ORO is trusted by Fortune 500 companies and fast-growing global organizations to automate processes, improve cross-team collaboration, and scale procurement operations. To learn more, visit orolabs.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Why Liverpool's Wirtz is causing concern at big pharma company Bayer
When attacking midfielder Florian Wirtz arrived at Liverpool Football Club (FC) from Bayer Leverkusen to the sound of jubilant supporters this summer, few anticipated that the transfer would cause concern at big pharma Bayer. Bayer – a German drugmaker that owns compatriot football club Bayer Leverkusen – reported better-than-expected Q2 results last week. Operating income came in at €2.1bn ($2.43bn) for the company, fuelled apparently by strong growth in its pharmaceutical portfolio. However, a more detailed Q2 earnings report released on 6 August revealed that the results included revenue from players sold at Bayer Leverkusen. In its Q2 report, Bayer wrote: 'In the reconciliation, earnings before interest, taxes, depreciation (EBITDA) before special items increased against the prior-year period, largely thanks to higher revenue from player transfers at Bayer 04 Leverkusen Fußball GmbH.' A Bayer spokesperson declined to add further information after Pharmaceutical Technology's request, saying only the player transfers 'helped improve this figure'. Despite a positive Q2 report that also included Bayer raising its 2025 sales outlook, investors were downbeat after the disclosure. Shares in the company closed 8% down at €24.98 on 6 August compared to the market open. There was also a lukewarm reception to in-depth analysis of its pharma segment, which showed that the 0.6% growth came more from a slower decline in sales of off-patent anticoagulant Xarelto (rivaroxaban). Investors usually hope that growth in newer products, with longer patent protection, will further fuel revenue. 'The detail of the beat being somewhat related to Xarelto and the sale of a footballer could be disappointing to some,' JP Morgan analysts wrote in a note sent to Pharmaceutical Technology. Leverkusen have permanently sold a total of six players in the summer transfer window for fees, according to Transfermarkt. The highest by far was Wirtz's transfer to Liverpool FC for a British-record fee of €136.3m in June. The deal structure includes €117.5m upfront for the player, meaning Leverkusen receive that immediately. Other deals include Jeremie Frimpong – also to Liverpool FC – for €40m in May and Odilon Kossounon transferred for €20m in June. German football league rules dictate that fan members maintain majority ownership and control of their clubs. Bayer's ownership of Leverkusen goes back to 1904, when the club was established, predating voting rights rules. It is unclear how much of Leverkusen's profits funnel back to Bayer. JP Morgan analysts specifically highlighted the Wirtz transfer driving lower reconciliation costs, which came in at an EBITDA of €13m, €106m better than consensus. Despite the noise around player transfers inflating earnings, there were distinct growth points for Bayer's newly launched drugs. Prostate cancer therapy Nubeqa (darolutamide) grew 50.5% to €546m, while Kerendia (finerenone) stretched sales by 67.1% to €183m. Separately, Bayer announced it has now cut 12,000 full-time positions since the start of its restructuring programme designed to save €2bn by 2026. "Why Liverpool's Wirtz is causing concern at big pharma company Bayer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Bayer Second Quarter 2025 Earnings: EPS Misses Expectations
Explore Bayer's Fair Values from the Community and select yours Bayer (ETR:BAYN) Second Quarter 2025 Results Key Financial Results Revenue: €10.7b (down 3.6% from 2Q 2024). Net loss: €199.0m (loss widened by 485% from 2Q 2024). €0.20 loss per share (further deteriorated from €0.035 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Bayer EPS Misses Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Performance of the German Pharmaceuticals industry. The company's shares are down 11% from a week ago. Risk Analysis It is worth noting though that we have found 1 warning sign for Bayer that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Corteva raises annual profit forecast after strong first-half performance
(Reuters) -U.S. agrichemicals company Corteva raised its annual adjusted profit forecast on Wednesday, following strong performance in the first half of the year. Reuters had reported in May that U.S. farmers have hit very few snags with corn planting this spring, and the foreseeable future is barrier-free. Corteva's net sales rose 5.6% to $6.46 billion during the second quarter, driven by higher sales in all its regions. The company is among the largest crop-protection product makers in the United States, competing with the likes of Syngenta and German firms BASF and Bayer in the agricultural chemicals sector. The company raised its forecast for full-year adjusted earnings to be between $3.00 to $3.20 per share, from a prior view of $2.70 to $2.95 per share.
